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Abstract
Clinical evidence suggests an association between galactosaemia and premature ovarian insufficiency (POI); however, the
mechanism still remains unresolved. Experimental galactose toxicity in rats produces an array of ovarian dysfunction
including ovarian development with deficient follicular reserve and follicular resistance to gonadotrophins that characterize
the basic tenets of human POI. The present investigation explores if galactose toxicity in rats attenuates the bioactivity of
gonadotrophins or interferes with their receptor competency, and accelerates the rate of follicular atresia. Pregnant rats
were fed isocaloric food-pellets supplemented with or without 35% D-galactose from day-3 of gestation and continuing
through weaning of the litters. The 35-day old female litters were autopsied. Serum galactose-binding capacity,
galactosyltransferase (GalTase) activity, and bioactivity of FSH and LH together with their receptor competency were
assessed. Ovarian follicular atresia was evaluated in situ by TUNEL. The in vitro effects of galactose were studied in isolated
whole follicles in respect of generation of reactive oxygen species (ROS) and expression of caspase 3, and in isolated
granulosa cells in respect of mitochondrial membrane potential, expression of p53, and apoptosis. The rats prenatally
exposed to galactose exhibited significantly decreased serum GalTase activity and greater degree of galactose-
incorporation capacity of sera proteins. LH biopotency and LH-FSH receptor competency were comparable between the
control and study population, but the latter group showed significantly attenuated FSH bioactivity and increased rate of
follicular atresia. In culture, galactose increased follicular generation of ROS and expression of caspase 3. In isolated
granulosa cells, galactose disrupted mitochondrial membrane potential, stimulated p53 expression, and induced apoptosis
in vitro; however co-treatment with either FSH or estradiol significantly prevented galactose-induced granulosa cell p53
expression. We conclude that the ovotoxic effects of galactose involves attenuation of FSH bioactivity that renders the ovary
resistant to gonadotrophins leading to increased granulosa cell expression of p53 and follicular atresia.
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Introduction
Premature ovarian failure, currently referred to as premature
ovarian insufficiency (POI), is a frequent finding in women with
galactosaemia [1–3]. Galactosaemia, an inherited inborn error of
the major galactose assimilation pathway caused by galactose-1-
phosphate uridyltransferase (GALT) deficiency, produces wide
phenotypes of ovarian dysfunction [4]. The prevalence of POI in
galactosaemic population is 1 in 10,000 for women between 15
and 29 years of age, and 7.6 in 10,000 for women aging between
30 to 39 [5]. In some women ovarian failure is a consequence of
premature depletion of follicular reserve (afollicular or follicle
depletion type of POI), while the other galactosaemic women do
exhibit the presence of follicles that are refractory to gonadotro-
phin stimulation and therefore suffer from arrested growth and
maturation (follicle dysfunction type of POI or resistant ovary
syndrome) [6]. Despite more than four decades of intense
research, the cause and effect relationships between galactosaemia
and POI, and the molecular mechanisms of galactose toxicity
remain elusive; however, the general consensus is that the ovarian
pathology is the aftermath of toxic effects of galactose and its
metabolites both at the ovarian and extra-ovarian levels [7–9].
Rodents placed on high galactose diet provide an excellent model
for galactose toxicity [10–12]. We have earlier demonstrated that
experimental galactose toxicity in rats produced an array of
ovarian dysfunctions that characterize the basic tenets of diverse
phenotypes of POI [13]. Embryos exposed to high galactose in
utero suffer from significant attenuation of germ cell migration and
develop ovaries with deficient follicular reserve [14]. Liu et al. [15]
reported that high galactose diet down regulated the oocyte-
specific growth factor, GDF-9, which is obligatory for folliculogen-
esis, and inhibition of follicular development was a secondary
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2consequence. Lai et al. [16] demonstrated that immature rats fed
with high galactose diet exhibited higher expression of Fas and
Fas-ligand but lower expression of Xiap and Riap, suggestive of
increased apoptotic damage of the ovary. These mechanisms,
however, could not explain the full spectrum of ovarian
dysfunction since normal adult mice with optimum follicular
reserve also exhibited ovarian failure in the form of follicular
resistance to gonadotrophins following exposure to high galactose
[17]. Thus the precise mechanisms underlying ovotoxic effects of
galactose is still far from clear.
We have demonstrated that galactose toxicity renders the ovary
refractory to gonadotrophins; but suppression of endogenous
gonadotrophins by GnRH receptor down regulation improves
ovarian response to exogenous gonadotrophins [13]. This
observation questions if the gonadotrophins produced under
galactose toxicity do possess normal bioactivity.
Reports indicate that galactosaemia interferes with the galacto-
sylation process. An abnormal glycosylation pattern has been
documented in some galactosaemic females with partial absence of
terminal disaccharides leading to synthesis of the neutral isoform
of FSH [18]. In vitro and in vivo experiments have shown that
deglycosylated FSH has a higher binding affinity to its receptor
than the glycosylated form, but is unable to activate the second
messenger system [19]. Despite a growing body of evidence
holding glycosylation defect and consequent loss of gonadotrophin
biopotency as the major causes of ovarian resistance to
gonadotrophins, the production of aberrant FSH isoform with
reduced bioactivity has been recently contradicted [20–21]. In
sheep, high doses of galactose inhibited FSH-induced differenti-
ation of granulosa cells cultured in vitro [7]. Fraser et al. [22]
suggested that an acquired anomaly of gonadotrophin receptors
perhaps attributes to the process. However, no direct evidence in
support of anomaly of gonadotrophin receptors is available so far.
Thus, the mechanism underlying the ovotoxic effects of galactose
remains unresolved.
The present investigation explores the possibility of galactosyla-
tion defect of gonadotrophins and seeks evidence if galactose
toxicity impairs bioactivity of gonadotrophins or their receptor
competency. It also addresses the effect of galactose on follicular
atresia and granulosa cell apoptosis.
Results
Effects of galactose in vivo
Serum capacity to bind galactose. In the presence of
purified GalTase, serum proteins of the galactose-exposed rats
exhibited significantly higher (P=0.007) incorporation of
radiolabeled galactose (fmol/mg serum protein) as compared to
the serum proteins from controls (galactose-exposed: 1.3260.02 vs.
control: 1.0960.07).
Serum galactosyltransferase (GalTase) activity. Serum
GalTase activity was assessed in respect of the capacity of serum to
catalyse the transfer of radiolabeled galactose from UDP-galactose
to ovalbumin (endogenous serum protein that also served as
galactose acceptor was not taken into account). The overall
catalytic transfer of radiolabeled galactose (fmol/mg protein) from
UDP-galactose to ovalbumin was significantly lower (P=0.0003)
in the presence of study sera (4.5260.32) as compared to that
under the influence of control sera (6.4960.30).
Serum gonadotrophic activity. Production of estradiol (E2)
by the cultured control granulosa cells under the influence of sera
from control and study population has been presented in
Figure 1A. E2 production, a measure of serum FSH-like activity,
increased significantly (P,0.0001) over the basal level almost in a
linear fashion in response to an increase in the volume of control
sera between 0.025–0.200 ml. By contrast, addition of same
volumes of study sera was not rewarded by any increase in E2
production over the basal level, suggesting attenuated serum FSH-
like activity of the galactose-exposed rats.
Figure 1B presents theca cell production of androstenedione in
response to different volumes of control and experimental sera that
served as the source of LH. Androstenedione production under the
influence of both control and study sera gradually increased over
the basal level, that were comparable between the groups. The
steroidogenic response under the influence of the highest volume
of study sera was marginally higher than that of the corresponding
volume of control sera; however, statistically the difference was not
quite significant (P=0.051).
Granulosa/theca cell competency to respond to FSH/
LH. Figures 2A and 2B present the comparative degree of FSH-
stimulated E2 and LH-stimulated androstenedione production,
respectively by granulosa and theca cells collected from both
control and study groups. In both groups, there was gradual rise in
granulosa cell production of E2 or theca cell production of
androstenedione in response to increments in the FSH and LH
doses, respectively; and the rates of increase were statistically
comparable between the groups. Thus granulosa and theca cell
competencies to respond respectively to FSH and LH are not
altered in galactose-treated rats.
Ovarian follicular atresia. Immunohistochemical detection
of follicular apoptosis by TUNEL demonstrated that the rate of
follicular atresia in the galactose-exposed rat ovaries (Fig. 3C)
increased as compared to the control group (Fig. 3B), which
showed significantly lower TUNEL labeling. Negative control
sections (exclusion of terminal TdT) demonstrated no TUNEL
reaction (Fig. 3A).
Effects of galactose in vitro
Follicular histoarchitecture. As compared to PBS-treated
control ones (Fig. 4A), follicles exposed to galactose at 50 nM
(Fig. 4B) and 100 nM (Fig. 4C) concentrations exhibited large
number of pyknotic granulosa cells arranged in asymmetric rings
that mark follicular degeneration [23].
Follicular ROS. Galactose treatment at 50 nM (Fig. 4E) and
100 nM (Fig. 4F) concentrations led to graded increase in ROS
generation over that of the untreated cultured follicles (Fig. 4D).
Follicular caspase 3. Immunoblot data showed dose-
dependent increase in the expression of the apoptosis-executor
protein, caspase 3, following treatment with galactose (Fig. 5A).
The level of caspase 3 protein relative to b-actin increased
significantly following treatment with galactose at 50 nM
(p=0.010) and 100 nM (p,0.0001) concentrations over that of
PBS-exposed controls (Fig. 5B).
Granulosa cell mitochondrial membrane potential. The
granulosa cells exposed to PBS or galactose at concentrations up to
25 nM concentration exhibited high mitochondrial polarization as
indicated by greenish orange fluorescence that marked JC-1
aggregation [only the PBS-exposed control picture (Fig. 6A) is
shown]. But at concentrations 50 nM (Fig. 6B) and 100 nM
(Fig. 6C), galactose gradually increased depolarization of
mitochondrial membrane as evidenced by change from greenish
orange fluorescence of JC-1 aggregates to green fluorescence of
JC-1 monomers.
Granulosa cell annexin V-affinity assay. Figures 6 D–F
present the merged images of annexin V and propidium iodide
(PI) fluorescence of granulosa cells cultured in the presence of PBS
(control) or galactose. Following exposure to galactose up to
25 nM concentration, the treated granulosa cells (not shown in the
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At 50 nM concentration of galactose (Fig. 6E), however, the cells
showed characteristic annexin V binding without PI staining,
indicating the intactness of plasma membrane. But at 100 nM
galactose concentration (Fig. 6E) the granulosa cells exhibited both
annexin V and PI fluorescence.
Granulosa cell p53 expression. Immunoblot analysis of
total p53 showed that the protein ran as a doublet and there were
relatively increased expressions in the galactose-treated granulosa
cells (Figure. 7A). Compared with PBS-exposed controls, the p53
protein expression relative to b-actin increased significantly
following treatment with galactose at 50 nM (p=0.015) and
100 nM (p,0.0001) concentrations (Fig. 7B).
Preventive effects of E2 and FSH on granulosa cell
expression of p53. Immunofluroscence detection of granulosa
cell p53 expression by confocal microscopy revealed that the
treatment of granulosa cells with 50 nM galactose (Fig. 8B) for
24 h increased the expression of p53 over that of untreated
controls (Fig. 8A). Co-treatments with either E2 at 100 pg/ml
(Fig. 8C) and 1 ng/ml (Fig. 8D) concentrations, or FSH at 25 ng/
ml (Fig. 8E) and 100 ng/ml (Fig. 8F) concentrations prevented
galactose-stimulated p53 expressions in a dose-dependent manner.
Figure 1. Follicular cell steroidogenic response to serum gonadotrophins. Granulosa and theca cells retrieved from ovaries of control rat
were cultured in the presence of both control and galactose-exposed rat sera. Serum FSH-like activity was evaluated with respect to granulosa cell
production of E2 (Fig. 1A), while theca cell production of androstenedione (Fig. 1B) was the measure of serum LH-like activity. Values are expressed as
mean 6 SEM of 4 determinations in each datum point. In Fig. 1A, the data points with different letters (a, b, c, d) differ significantly (P,0.0001). In
Fig. 1B, androstenedione production under the influence of 200 ml study serum was comparatively higher than that of control sera but the difference
does not reach the significance level.
doi:10.1371/journal.pone.0030709.g001
Figure 2. Granulosa and theca cell steroidogenic response to standard gonadotrophins. Granulosa and theca cells retrieved from both
control and galactose-exposed rats were cultured in the presence of standard gonadotrophins. Steroidogenic response was evaluated with respect to
FSH-induced granulosa cell production of E2 (Fig. 2A) and LH-induced theca cell production of androstenedione (Fig. 2B). Data points represent the
mean 6 SEM of 4 similar cultures. The figures show gradual increase in the production of E2 as well as androstenedione in the control and study
groups in response to increase in the levels of FSH and LH, respectively, and the rate of increase does not differ significantly between the groups.
doi:10.1371/journal.pone.0030709.g002
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The precise mechanisms underlying impairment of ovarian
function in classical galactosaemia are not known; nevertheless
galactose and its metabolites are thought to play contributory roles
at the ovarian level. The present study demonstrates that galactose
toxicity attenuates FSH bioactivity and exerts direct ovotoxic
effects.
In order to address the ovotoxic effects of Galactose, we adopted
both in vivo and in vitro approaches. The in vivo effects of galactose
toxicity were investigated in a previously described rat model that
exhibited elevated blood levels of galactose and galactose-1-
phosphate accompanied by characteristic phenotypes of POI
including elevated serum gonadotrophins, resistance to gonado-
trophins and delayed onset of puberty [13]. In our rat colony the
mean age at onset of puberty is post-natal day (PND) 37. The
present evaluations were therefore performed on PND 35, when
the execution of the toxic effects of galactose is expected to be fully
operational.
Since in vivo studies do not allow us to judge whether the ovarian
effects of galactose are executed directly at the ovarian level or
through systemic route, we performed some investigations in vitro.
This was done in agreement with the animal ethics guidelines that
recommended the use of minimal number of rats to the possible
extent. Because of deficient follicular reserve, retrieval of necessary
number of follicles/follicular cells from rats treated with galactose
in vivo would have required large number of experimental rats,
while for in vitro studies we could retrieve follicles/granulosa cells
from 35-day old control rats that had good follicular yield because
of optimum follicular reserve.
Our first approach was to evaluate the possibility of galactosyla-
tion defect under galactose toxicity. We followed the method
adopted by Prestoz et al. [18] that determined the extent of
galactose-acceptance capacity of serum glycoproteins in vitro in the
presence of GalTase and sufficient UDP-galactose, which served
as the galactose donor. Normally galactose is linked to N-acetyl
glucosamine (GlcNAc) in the carbohydrate moieties of glycopro-
teins. The rationale for this approach was that any interference
with the process of galactosylation would result in a greater
number of glycoprotein oligosaccharides being terminated in
GlcNAc. This would have increased capacity to accept galactose
from radiolabeled UDP-galactose in the presence of purified
GalTase. We observed a greater magnitude of galactose
incorporation in the study sera, which is suggestive of a greater
Figure 3. Immuno-histochemical detection of ovarian apoptosis by TUNEL. Ovarian apoptosis was evaluated by TDT-mediated dUTP nick-
end labeling in representative sections from control (Fig. 3B) and galactose-exposed rats (Fig. 3C). The galactose-exposed rat ovaries show higher
population of TUNEL sensitive cells as compared to controls. Negative control section (exclusion of terminal TdT) demonstrates no TUNEL reaction
(Fig. 3A).
doi:10.1371/journal.pone.0030709.g003
Figure 4. Histological assessment of follicular architecture and evaluation of follicular ROS generation. Histological pictures
demonstrate that the follicles treated with galactose at 50 nM (Fig. 4B) and 100 nM (Fig. 4C) concentrations exhibit large number of atretic cells as
compared to the untreated one (Fig. 4A). Follicles exposed to galactose at 50 nM (Fig. 4E) and 100 nM (Fig. 4F) concentrations show dose-dependent
increase in intracellular ROS generation over that of the untreated control (Fig. 4D), as evaluated by fluorescence microscopy.
doi:10.1371/journal.pone.0030709.g004
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produced under galactose toxicity. It may however be mentioned
that although the culture was conducted in the presence of 1 mgo f
purified GalTase, the catalyzing reaction might have also been
influenced by the endogenous serum GalTase activity. But it is
significant to note that the increased serum binding of galactose in
the study group occurred despite then having lower endogenous
GalTase activity than control sera (described in subsequent
section).
The enzyme GalTase catalyzes transfer of galactose from UDP-
galactose to the terminal GlcNAc residues on the oligosaccharide
complex in the process of galactosylation. Galactosaemia is
associated with accumulation of galactose-1-phosphate and
deficient production of UDP-galactose [24]. By measuring liver
epimerase activity, we have earlier provided evidence for deficient
UDP-galactose synthesis in rats under experimental galactose
toxicity [13]. There is a report that accumulated galactose-1-
phosphate may have inhibitory impact on GalTase activity [25].
To address the issue if galactose toxicity interferes with GalTase
activity, we evaluated serum GalTase activity with respect to its
capacity to catalyze the transfer of labeled galactose from UDP-
galactose to ovalbumin. Reports indicate that irrespective of tissue
origin, any significant alteration in GalTase activity is reflected in
serum GalTase levels [26]. This remains the basis of assessing
GalTase level in serum, instead of pituitary, which is the site of
glycoprotein hormone (FSH/LH) synthesis. The present investi-
gation demonstrated that the sera from galactose-exposed group
had comparatively decreased capacity to catalyze the transfer of
galactose from labeled UDP-galactose to the accessible GlcNAc
terminal of ovalbumin under optimized culture condition. Taking
the earlier report [13] and present findings together, a consensus
can be made that restricted availability of UDP-galactose and
attenuated GalTase activity perhaps rate-limit the process of
galactosylation under galactose toxicity.
Gonadotrophins are members of the glycoprotein family of
hormones. Carbohydrates attached to the protein core of these
hormones influence a number of intracellular and extracellular
processes including activation of the respective receptors and
efficient triggering of signal transduction. It therefore appears
logical to envisage a critical impact of galactose toxicity and
consequent attenuation of galactosylation process on the biological
activity of gonadotrophins.
Galactose toxicity increases serum levels of FSH and LH as
measured by immunoassay [13]. As a measure of FSH-LH
bioactivity, we evaluated serum gonadotrophic activity in vitro,
which was based on the capacity of serum to stimulate
steroidogenesis by granulosa and theca cells of control origin.
The volumes of sera were selected in such a manner that they
represented gonadotrophins at levels not exceeding the physiolog-
ical range but were capable of stimulating E2/androstenedione
production at concentrations within the detectable range of our
assay system. The selection of sera volumes was therefore based on
the pre-optimized doses of reference gonadotrophins that were
shown to elicit measurable steroidogenic response in our culture
set-up and the physiological range of serum gonadotrophins in rats
[13]. The culture studies clearly demonstrated that sera from both
control and galactose-exposed rats were almost equipotent in
stimulating theca cell production of androstenedione (Figure 1B).
Marginally increased rate of androstenedione production by the
sera of galactose-exposed rats over that of respective volume of
control sera might be attributed to elevated serum LH levels under
galactose toxicity [13]. By contrast, despite having elevated levels
of FSH [13], the study sera hardly exhibited any FSH-like
bioactivity (Figure 1A). Galactose represents an important
constituent of the carbohydrate side chain of FSH but not of
LH [27]. So the observations taken together suggest that galactose-
deficient variant(s) of FSH that lack bioactivity are perhaps
produced under galactose toxicity.
Glycosylation defect in galactosaemia was first suggested by
Haberland et al. [28] and further attested by many investigations
[18,29–35]. The loss of bioactivity following deglycosylation of
FSH (27) and weaker FSH bioactivity in galactosaemic women
[18] are in good agreement with each other. The present findings
are therefore reminiscent of the earlier studies [18,28–35] linking
deficient galactosylation and attenuated biopotency of FSH. But
reports that demonstrate no significant differences in either FSH
isoforms [20] or FSH bioactivity [21] in the galactosaemia patients
are contrary to these observations. By using Chinese hamster cells
transfected to express human FSH receptors that produce cAMP
in response to activation by FSH, Sanders et al. [21] demonstrated
no loss of FSH bioactivity in galactosaemic women. No definite
explanation can be put forward to explain this discrepant finding
on FSH bioactivity in human galactosaemia and experimental
galactose toxicity. However, it may be important to note that in
normal women circulating FSH bioactivity is associated with
isoforms with different oligosaccharide structures [36], and
changes in gonadotrophin isoform occur through the different
phases of menstrual cycle [37]. Thus FSH bioactivity significantly
differs between the different phases of the same cycle, with highest
bioactivity at mid-cycle [37]. Sanders and co-workers [21] were
not particular about the phase of the menstrual cycle of the control
subjects, when the blood was drawn for the assessment of FSH
bioactivity. The finding of comparable FSH bioactivity between
the control and galactosaemia women might not be highly unlikely
Figure 5. Immunoblot and densitometric analysis of caspase 3.
Representative immunoblots of caspase 3 protein expressions in
follicles cultured in the absence (control) and presence of galactose
show dose-dependent increase in the expressions of cleaved form of
caspase 3 protein in comparison to the untreated one (Fig. 5A). Both
bands of caspase 3 were used for quantification. Compared with
controls, the level of caspase 3 protein relative to b-actin increased
significantly following treatment with galactose at 50 nM (p=0.010)
and 100 nM (p,0.0001) concentrations (Fig. 5B).
doi:10.1371/journal.pone.0030709.g005
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FSH bioactivity was the lowest [38]. However, further studies are
needed to delineate the precise factors that account for the
disparity in FSH bioactivities between the investigations.
It may be relevant to note in this context that unlike POI,
testicular dysfunction is not a very frequent finding in human
galactosaemia. Also, in a rat model for galactosaemia, Chen et al.
demonstrated no corresponding testicular toxicity [39]. Differen-
tial ovarian and testicular resistance to galactosaemia is perhaps
due to the facts that expression of GALT is lowest in testis [39]
that makes this organ less vulnerable to galactose toxicity, and that
FSH does not play an obligatory role in the maintenance of
spermatogenesis [40] unlike in folliculogenesis.
Fraser et al. [22] suggested that perhaps an acquired anomaly of
gonadotrophin receptors also attributes to the process of follicular
resistance to gonadotrophins. We addressed the issue by evaluating
steroidogenic response of the target follicular cells to reference
gonadotrophin preparations. The results clearly demonstrate that
both granulosa and theca cells from galactose-exposed ovary
responded as effectively as the control follicular cells responded to
FSH and LH to produce E2 and androstenedione, respectively
(Figure 2 A & B). This observation refutes the proposition of
receptor anomaly as the cause of follicular gonadotrophin
resistance inducted by galactose toxicity.
It is indeed appropriate in this context to refer to our
observation that the galactose-exposed rat ovaries that were
normally refractory to gonadotrophin stimulation, responded well
when endogenous gonadotrophins were suppressed by GnRH
receptor down-regulation [13]. Earlier workers have demonstrated
that deglycosylated FSH has higher binding affinity to its receptor
than the glycosylated form, but is unable to activate second
messenger system and thereby exert antagonistic effects at the
receptor levels [19]. This very characteristic feature of deglyco-
sylated forms of FSH explains why the ovary could respond
favourably to exogenous gonadotrophins only after endogenous
gonadotrophins were suppressed by pituitary desensitization [13].
Apoptotic death of follicles is an essential phenomenon in
ovarian physiology occurring at all periods of life. That elevated
galactose levels favour the activation of rat ovarian apoptosis has
been substantiated earlier by the increased expression of
apoptosis–mediating proteins and down-regulation of anti-apo-
ptotic proteins [16]. The present observation on ovarian TUNEL
reaction provides direct evidence in support of increased follicular
apoptosis under experimental galactosaemic state.
Classical galactosaemia is characterized by deficiency of GALT
and consequent intracellular accumulation of galactose, galactose-
1-phosphate and galactitol. Two metabolites are potentially toxic:
galactitol is responsible for the cataracts, while galactose-1-
phosphate causes the rest of the pathology [41]. Ovary is the
second richest organ for the expression and activity of GALT, and
is therefore one of the most likely organs to accumulate galactose
and galactose-1-phosphate in galactosaemia and get affected by
their direct ovotoxic effects, if any [4]. We, therefore, examined
the effects of galactose on isolated whole-follicle and granulosa
cells in vitro.
To the best of our knowledge, there are no reports on the
ovarian concentrations of galactose in human or experimental
galactosaemia. To optimize the galactose doses for in vitro studies,
Figure 6. Potential-dependent mitochondrial JC1 staining and evaluation of apoptosis with annexin V. Images of mitochondrial JC-1
fluorescence in granulosa cells are presented in Figs. 6 A–C. The granulosa cells were cultured for 24 h in the presence of PBS (control) or galactose
followed by incubation with JC-1 for 30 min at 37uC in dark. Cells were washed, fixed, and analyzed by confocal microscopy. The PBS-treated control
group (Fig. 6A) shows greenish orange florescence in most of the cells due to strong JC-1 aggregation that marks high mitochondrial membrane
potential. The cells treated with galactose at 50 nM (Fig. 6B) and 100 nM (Fig. 6C) concentrations show gradual shifting from greenish orange to
green fluorescence indicating disruption of mitochondrial membrane potential. Merged images of annexin V and propidium iodide (PI) fluorescence
in granulosa cells are presented in Figs. 6 D–F. The granulosa cells were cultured on poly L-lysine coated coverslips for 24 h in the presence of PBS
(control) or galactose, followed by incubation with Annexin V-FITC and propidium iodide for 15 min at room temperature in dark. Cells were washed,
fixed and visualized under confocal microscope. The PBS-treated control cells (Fig. 6D) show no annexin V binding. The cells treated with 50 nM
galactose (Fig. 6E) show annexin V binding but no PI fluorescence, which mark the exposure of phosphadidylserine at the outer leaflet with intact
membrane integrity. That the cells are apoptotic but not dead is indicated by the absence of red fluorescence of PI. The cells exposed to 100 nM
galactose (Fig. 6F), by contrast, are clearly positive for both annexin V and PI fluorescence, which is indicative of loss of membrane integrity
characterizing apoptotic death.
doi:10.1371/journal.pone.0030709.g006
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mitochondrial membrane potential and annexin-V affinity assays
at concentrations ranging between 10–100 nM. Since no effects
could be appreciated up to 25 nM concentration, we performed
all culture studies in the presence of 50 nM and 100 nM galactose
that are well below the blood galactose level (,350 nM) under the
present experimental situation [13].
In the whole-follicle culture, galactose dose-dependently in-
creases follicular generation of ROS and caspase 3. This clearly
suggests the direct atretic effects of galactose because ROS is the
initiator of apoptotic cascade in granulosa cells [42], while caspase
3 is the key executor of all apoptotic processes [43]. A complex
interactive network between the three follicular compartments -
the oocyte, granulosa cells and theca cells - is operative in
determining the fate of a follicle [44]. Reports indicate that
follicular atresia is driven by the apoptosis of granulosa cells that
secondarily leads to oocyte death. A number of intracellular
molecules are possibly directly involved in the regulation of this
process. GDF-9 is an oocyte-specific factor that plays a pivotal role
in maintaining oocyte-granulosa-theca cell communications to
promote follicular differentiation and maturation [45]. There is an
earlier report that galactose significantly down regulates ovarian
GDF-9 [15]; increased follicular atresia was considered a
secondary consequence. We, however, observed that galactose
can directly trigger granulosa cell apoptosis in vitro.
Viable cells maintain a strictly asymmetric lipid bilayer
composition between the inner and outer leaflets of the plasma
membrane, with phosphatadylserine (PS) residues at the cyto-
plasmic face [46]. Apoptotic cell death is accompanied by loss of
phospholipid asymmetry in membrane structure by surface
exposure of PS molecules at the outer membrane leaflet, while
the membrane integrity remains unchallenged. Annexin V
cannot penetrate viable cell membrane and therefore cannot
bind PS, but it can bind with high affinity to the exposed PS in
the presence of calcium [47]. Our confocal microscopic pictures
of annexin V-affinity binding assay clearly demonstrate that
following exposure to galactose at 50 nM concentration, the
granulosa cell surfaces are annexin V-positive, but negative for
staining by the membrane impermeable DNA stain PI. This
indicates that galactose induces granulosa cell apoptosis. How-
ever, at 100 nM doses some cells showed PI fluorescence, which
is indicative of cell death.
Reports suggest that early during apoptosis, cells undergo
disruption of the mitochondrial transmembrane potential prior to
PS exposure at the outer membrane leaflet [48]. JC-1 is a
lipophilic cationic fluorescent dye that can enter selectively into
mitochondria and act as a dual emission probe. As the membrane
potential increases, JC-1 aggregates and changes its colour from
green to orange, while it maintains the green colour of its
monomeric form as the mitochondrial membrane potential
depolarizes [49]. The confocal microscopic picture following JC-
1 staining shows that galactose at 50 nM and higher concentra-
tions disrupted the mitochondrial transmembrane potential. This
finding also supplements the findings of annexin V binding.
Apoptosis can be activated either by endogenous intrinsic
pathways resulting from an imbalance between pro-apoptotic and
anti-apoptotic factors, or by exogenous extracellular mechanism
[43]. Recent study documents that p53-mediated intrinsic death
pathways is central in the induction of follicular atresia [50]. Our
western blot and immunofluorescence analyses also showed that
galactose dose-dependently up-regulated granulosa cell expres-
sion of p53 and disrupted mitochondrial membrane potential in
vitro.F S Ha n dE 2 belong to the anti-apoptotic factors that
significantly impact follicular survival [43]. The anti-apoptotic
effect of FSH is mediated in part by suppression of ROS [42].
Since galactose toxicity attenuates FSH bioactivity and sets back
granulosa cell production of E2, the resultant follicular microen-
vironment perhaps suffers from deficiency of two major anti-
apoptotic factors. We hypothesize that in our experimental
galactosaemia rat model, galactose can directly induce follicular
oxidative stress, which is not taken care of by FSH because of its
attenuated bioactivity. Consistent with this proposition are our
findings that co-treatment with FSH or E2 effectively prevented
galactose-induced granulosa cell expression of p53. This finding is
important with respect to its therapeutic implications. It is
pertinent in this respect to refer that several patients with classical
galactosaemia and ovarian dysfunction responded to exogenous
gonadotrophin administration, either by ovulating or by docu-
mented estrogen production [51], and pregnancy has been
reported in galactosaemia patient after down-regulation of
endogenous gonadotrophins followed by stimulation with recom-
binant FSH [52]. However, treatment with exogenous gonado-
trophins is practically difficult to generalize since this can be a
rational treatment option only for the subgroup of women with
residual follicle reserve.
In conclusion, galactose exerts its ovotoxic effects perhaps at
multiple levels. Ovarian accumulation of galactose and galactose-
1-phosphate may exert direct apoptotic effects, while the extra-
ovarian effect of galactose may involve attenuation of FSH
bioactivity followed by withdrawal of protection from ROS insult
and activation of p53-mediated granulosa cell apoptosis.
Figure 7. Immunoblot and densitometric analysis of p53. A
representative immunoblot of p53 protein expression in cultured
granulosa cells shows dose-dependent increase in its expression of p53
in the galactose-treated (50 nM; 100 nM) cells over that of the control
(Fig. 7A). The histogram represents the relative intensity of the bands
normalized to loading control. Quantification of p53 Western blots was
done by the ratio of p53 to b-actin. Both bands of p53 doublet were
used for quantification. Compared with controls, the expression of p53
protein relative to b-actin increased significantly following treatment
with galactose at 50 nM (p=0.015) and 100 nM (p,0.0001) concentra-
tions (Fig. 7B).
doi:10.1371/journal.pone.0030709.g007
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e30709Figure 8. Reversal of galactose-induced granulosa cell p53 expression by co-treatment with E2 and FSH. Figure 8 demonstrates
galactose effects on the granulosa cell expressions of p53 in the presence or absence of E2 and FSH. The granulosa cells were cultured for 24 h with
PBS (control) or 50 nM galactose in the presence or absence of E2 and FSH, followed by overnight incubation with p53 antibody at 4uC. Cells were
washed, incubated with secondary antibody, fixed, and analyzed by confocal microscopy. Galactose exposure (Fig. 8B) up-regulates granulosa cell
p53 expression over that of untreated control (Fig. 8A). Co-treatment with 100 pg/ml E2 (Fig. 8C) or 25 ng/ml FSH (Fig. 8E) partially reversed the
galactose-induced expression of p53, while co-treatment with E2 at 1 ng/ml concentration (Fig. 8D) or FSH at 100 ng/ml concentration (Fig. 8F)
reversed the p53 expression back to control level (Fig. 8A).
doi:10.1371/journal.pone.0030709.g008
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Chemicals and reagents
Most of the chemicals including D-galactose, bovine serum
albumin (BSA), MnCl2, GalTase (from bovine milk), UDP-
galactose, Adenosine 5
/-monophosphate (5
/ AMP), MES (2-[N-
Morpholino] ethanesulphonic acid), trichloroacetic acid (TCA),
ovalbumin, diethylstilbestrol (DES), McCoy’s 5a medium (modi-
fied), Medium 199 (M 199) (with Earle’s salts, L-glutamine and
25 mM HEPES), 5,59,6,69 tetrachloro-1,19,3,39-tetraethylbenzi-
midazolcarbocyanine iodide (JC-1), human chorionic gonadotro-
phin (hCG), haematoxylin, insulin, transferrin, linoleic acid,
selenium, 2_, 7_-dichlorofluorescein diacetate, goat serum, and
pregnant mare serum gonadotrophin were purchased from Sigma
Chemical Co., St. Louis, MO, USA. Nutrient mixture HAM’S F-
10 with L-glutamine (1.0 mM) and sodium bicarbonate (1.2 g/l)
(Hyclone, Logan, Utah), Modified eagle’s medium (Gibco
TM
Invitrogen corporation), Uridine diphospho-D-[6-
3H]galactose,
ammonium salt (Amersham Pharmacia Biotech UK Limited,
Buckinghamshire, England), mounting medium for fluorescence
(Vector laboratories Inc. Burlingame), TdT-FragEL
TM DNA
fragmentation kit (Oncogene Research Products, Cambridge,
MA), RPMI 1640 media (Gibco, Grand Island, NY), eosin (s.d.
fine-chem. Ltd, Mumbai, India), Poly-L-Lysine coated slides and
four chambered slides (BD biosciences, Bedford, MA), Immobo-
lin–P membranes (Millipore Crop, Billerica, MA), Annexin V-
FITC apoptosis detection kit (BioVision, Mountain View, CA),
immuno reagents for western blot analysis of p53 and b-actin
(Santacruz Biotechnology, Santacruz, CA), secondary antibody
Alexa 633 (Invitrogen Corporation, Carlsbad, CA) and super
signal west pico chemiluminescent substrate (Thermo Scientific,
Rockford, USA) were procured from the respective commercial
sources. Rat FSH and LH reference preparations (rFSH-RP2 and
rLH-RP3) were procured from National Hormone and Pituitary
Programme, NIDDK, USA. Isocaloric food pellets (carbohydrate:
65.5%, protein: 21%, fat: 5.5%, mineral mixture: 7% and vitamin
mixture: 1%), supplemented with or without 35% galactose, were
prepared in the institute’s animal house.
Animals
The experiments were performed in accordance with the
guidelines formulated by the Committee for the Purpose of
Control and Supervision of Experiments on Animals, Ministry of
Culture, India, with approval from the Animal Ethics Committee
of Indian Institute of Chemical Biology (ID: 147/1999/CPCSEA/
SNK-P8/08-08-2005). Pregnant Sprague-Dawley rats, procured
from the random bred colony of the animal house of our institute,
were maintained under good husbandry conditions supported by
diurnal cycles of 12 h light and 12 h darkness with lights on at
0600 h daily. They were fed standard food pellet supplemented
with or without 35% D-galactose from day 3 of conception
continuing through weaning of the litters on postnatal day (PND)
21. On PND 35, few female pups from both control and treated
groups were sacrificed, blood was collected by direct cardiac
puncture and ovaries were dissected out. Sera were separated and
evaluated for galactose incorporation capacity, GalTase activity,
and gonadotrophin bioactivity, while ovaries were fixed and
processed for the assessment of follicular atresia by TUNEL
reaction. Other female litters from both groups received
subcutaneous (sc) injection of DES (2 mg/rat/day) for 4 days
and were sacrificed. Granulosa and theca cells were collected from
the ovaries and cultured for the assessment of gonadotrophin
receptor competency. The in vitro effects of galactose were assessed
in whole follicles or isolated granulosa cells obtained from 35-day
old control rats injected sc with DES (2 mg/rat/day) for 4 days, or
PMSG (25 mIU/rat/day) for 2 days. The procedures are
described in details under the heading of individual studies.
In vivo studies
Incorporation of UDP-(
3H) galactose into sera pro-
teins. Sera from 35-day old rats from the galactose-exposed
(n=12) and control (n=10) ones were tested for their capacity to
incorporate galactose in the presence of radiolabeled UDP-
[
3H]galactose and commercially available GalTase, following the
method of Ornstein et al. [33] with little modification. Each assay
mixture (final volume 35 ml) contained 225 mg of serum protein (as
determined by the method of Lowry et al. [53] using BSA as
control), 50 mM/L MnCl2,1mg GalTase, 50 mmol/L MES and
15 mmol/L 5
/ AMP at pH 6.5. The mixture was incubated at
37uC for 3 h. Enzyme activity was stopped thereafter and protein
was precipitated by the addition of 10% TCA followed by
centrifugation at 12006g for 15 min. The pellet was washed twice
in 0.1 N NaOH and finally counted in a Beckman LS-500 TD
Liquid Scintillation Counter.
Assay of serum galactosyltransferase activity. Sera from
control (n=10) and galactose-exposed (n=12) rats were evaluated
for their relative GalTase activity by following the principle
adopted for the galactose incorporation study; however, instead of
using serum protein as the galactose acceptor and commercial
GalTase as the catalytic enzyme, this assay utilized 235 mgo f
ovalbumin (150 mM) as the galactose acceptor [54] and serum as
the source of GalTase.
Collection and culture of granulosa cells. The in vitro assays
for FSH activity and its receptor competency were performed using an
in vitro granulosa cell culture method developed by Jia and Hsueh [55]
with modification [56] that uses aromatase activity in rat granulosa
cells as an index of FSH bioactivity. The rats were treated with
subcutaneous injection of DES (2 mg/rat/day) for 4 days [57].
Granulosa cells were released from their ovaries by puncturing follicles
and cultured for 24 h at 37uCi na5 %C O 2 incubator. Each well
contained approximately 1610
6 viable cells in 0.5 ml of Ham’s F10
medium, supplemented with L-glutamine (2 mM), BSA (100 mg/l),
penicillin (100 IU/ml), streptomycin sulphate (100 mg/ml), 1-(3-
isobutyl)-1-methylxanthine (0.125 mM), DES (10
24 M), insulin
(1 mg/ml), hCG (100 mg/ml), and androstenedione (10
26 M) as the
substrate for aromatase. The culture was conducted in the presence of
FSH reference preparation and/or serum, as the situation demanded.
The selected concentrations of FSH corresponded to the normal
physiological range in the same age group [13]. On completion of
incubation, the medium was aspirated and centrifuged. The resultant
supernatants were stored frozen at 240uCu n t i lE 2 was measured by
fully automated chemiluminescence assay using specific E2 assay kit
(ACS 180, Chiron Diagnostics Corp., East Walpole, MA, USA). The
assay sensitivity was 10 pg/ml; both intra- and inter-assay coefficients
of variation (COV) were ,8%.
Examination of serum FSH activity. Granulosa cells
(,1610
6) of control ovarian origin were incubated in the
presence of sera from control (n=8) and galactose-exposed
(n=13) rats at four different volumes between 25 and 200 mli n
a total incubation volume of 0.5 ml. Serum FSH activity was
assessed with respect to its capacity to stimulate granulosa cell
production of E2, expressed as picogram per ml culture medium,
and plotted against each volume of serum to construct dose-
response curves.
Examination of granulosa cell competency to respond to
FSH. Granulosa cells were collected from ovaries of PND 35
control (n=10) and galactose-exposed (n=33) rats. Because of
poor yield of cells in the study group, the granulosa cells were
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incubated in the presence of rat FSH reference preparation in the
range between 0.25 and 2 ng per tube. The production of E2 in
respect of each concentration of FSH was measured and a dose-
response curve was plotted.
Collection, purification and culture of theca cells. The in
vitro bioassays for LH and its receptor competency relied on
androstenedione production by purified rat theca cells, prepared
using the procedure described by Magoffin and Erickson [58].
Briefly, ovaries from DES-treated immature female rats were
punctured gently in ice cold M199 medium, and theca cells were
purified by an optimized discontinuous percoll density gradient
centrifugation procedure, as described by Magoffin and Erickson
[59]. Approximately ,10
5 purified rat theca cells were cultured in
500 ml of McCoy’s 5a medium supplemented with L-glutamine
(2 mM), penicillin (100 IU/ml) and streptomycin sulphate
(100 mg/ml) for 48 h at 37uCi n5 %C O 2 in the presence of
standard LH and/or serum samples. After incubation, the
medium was collected and stored frozen at 240uC for
subsequent analysis of androstenedione by an automated
chemiluminescence assay system (Immulite 2000: Diagnostic
Products Corp., USA). The assay sensitivity was 0.3 ng/ml, and
intra-and inter-assay COV were 5.2% and 8%, respectively.
Examination of serum LH activity. Theca cells of control
ovarian origin were incubated in the presence of sera from control
(n=8) and galactose-exposed (n=13) rats at 3 different volumes
between 50–200 ml. Androstenedione production rates were
expressed as nanogram per ml.
Examination of theca cell competency to respond to
LH. Theca cells collected from control (n=9) and galactose-
exposed (n=42) rats were incubated in the presence of rat LH
reference preparation in the range between 0.5–5.0 ng that
corresponded to the normal physiological range of serum LH in
the same age group [13]. Because of poor yield of cells in the study
group, they were pooled from 3/4 rats. The production of
androstenedione in respect of each concentration of LH was
measured and a dose-response curve was plotted.
Effects of galactose on follicular atresia. Immunohis-
tochemical detection of follicular apoptosis was done by in situ 3
/-
end labelling of DNA fragments in ovarian sections using the TdT-
mediated dUTP nick-end labeling (TUNEL) assay according to
the instructions given in the kit manual. Briefly, ovaries from
control (n=9) and galactose-exposed rats (n=11) were immerse-
fixed in 10% neutral buffered formalin at 4uC, dehydrated,
embedded in paraffin, and serially sectioned at 5 mm thickness.
Deparaffinized tissue sections were incubated with proteinase K
(20 mg/ml) in a humidified chamber for 15 min and endogenous
peroxidase activity was removed by treatment with 3% H2O2 for
10 min. Sections were then incubated with TdT labeling buffer at
37uC for 1 hr in a moist chamber. They were stained with
diaminobenzidine as a peroxidase substrate and counterstained
with methyl green. For control experiments, the enzyme
incubation step was omitted. Reaction was documented by
digital photography.
In vitro Studies
Follicle culture. The immature female rats were injected
subcutaneously with 10 IU of PMSG in 0.1 ml sterile 0.9% saline
[42]. After 24 h the animals were euthanized, ovaries were
removed, and the follicles at early antral stage of maturity and
measuring 150–200 mm in diameter were dissected out. Without
any assessment of oocyte maturity, the follicles were cultured by
the method previously described by McGee et al. [60]. Briefly, the
culture was continued for 24 h in Modified Eagle’s Medium
supplemented with ITS1 (insulin, 10 mg/L; transferrin, 5.5 mg/L;
linoleic acid, 4.7 mg/L; selenium, 5 mg/L) and Pen/Strep
(penicillin, 100 U/ml; streptomycin, 100 mg/ml) in the presence
of PBS or galactose (50 nM and 100 nM) and overlaid with sterile
mineral oil at 37uC in a moist atmosphere of 5% CO2 and 95%
air. On completion of incubation the follicles were collected for the
following analyses.
Histological analysis of follicles. Follicles were fixed in 4%
paraformaldehyde solution, embedded in paraffin and sectioned
(5 mm). Sections were stained with haematoxylin and eosin and
examined under light microscope. Eight to ten follicles from each
treatment group were analyzed, and 1 representative follicle from
each group was photographed.
Detection of follicular ROS generation in situ. Follicular
generation of ROS was evaluated according to Turton et al [42]
with little modifications. Briefly, the control and galactose-treated
follicles were washed with PBS and incubated with 100 mm 2_, 7_-
dichlorofluorescein diacetate (H2DCFDA) in MEM media for
30 min. ROS-mediated oxidative transformation of H2DCFDA to
fluorescent dichlorofluorescein was evaluated by fluorescence
microscopy as the measure of ROS.
Western blot analysis of follicular caspase 3. Twenty
follicles from the control and each treatment groups (50 nM and
100 nM) were collected in Eppendorf tubes in lysis buffer (50 mM
Tris-HCl, 150 mM NaCl, 1% SDS, 5 mM EGTA, 0.5 mMMgCl2,
0.5 mM MnCl2 and 0.2 mM phenylmethylsulfonylfluoride supple-
mented with protease inhibitor). These were homogenized with a
glass rod and centrifuged at 7500 rpm for 10 min at 4uC. The
supernatant was collected and estimated for protein concentration.
Fifty microgram of total protein from each sample was resolved on a
10% sodium dodecyl sulfate polyacrylamide gel and transferred onto
immobilon-P membranes. The membrane was incubated with 5%
blocking solution (Tris-buffered saline [TBS] containing 0.1%
Tween-20, 5% non-fat dried milk) for 2 h, washed with TBS
containing 0.1% Tween-20, and incubated overnight with rabbit
polyclonal anti-caspase 3 antibody (1:800) and anti-b-actin-antibody
(1:1000). HRP-conjugated secondary mouse anti-rabbit antibody
(1:2000)was added and peroxideactivitywasvisualizedbyenhanced
chemiluminescence and exposed to X-Ray film. Densitometric
quantification of signals was done by Image-J software. The data
were expressed as caspase 3 to b-actin ratio.
Granulosa cell isolation and preparation. The ovarian
granulosa cells from DES-treated control immature rats were
collected in ice-cold PBS, centrifuged, washed, and re-suspended
in RPMI medium. The cells were cultured on poly L-lysine-coated
microscopic glass slides in the presence of PBS or galactose at
concentrations ranging from 10 nM to 100 nM in humidified
atmosphere containing 5% CO2 and 95% air at 37uC for
24 hours, and analyzed for mitochondrial membrane potential,
annexin V-affinity binding, and western blot analysis of p53. The
cell viability was more than 90% in all sets of experiments, as
measured by trypan blue dye exclusion test.
Detection of granulosa cell mitochondrial membrane
potential. Analysis of mitochondrial membrane potential
was done by staining with JC-1, a lipophilic cationic
fluorescent dye capable of selectively entering mitochondria
and acting as a dual emission probe that reversibly changes color
from green (FL-1) to greenish orange (FL-2) in concert with
polarization of mitochondrial membrane [61]. On completion of
culture for 24 h, the granulosa cells were incubated with JC-1
for 30 min at 37uC in darkness. Cells were washed with PBS.
The cover slips were inverted on glass slides, fixed in 2%
formaldehyde, and analyzed by confocal microscopy (Nikon,
A1R, Japan).
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granulosa cells on the poly L-lysine coated coverslips were flooded
with 500 ml of 1X binding buffer, 5 mL of Annexin V-FITC, and
5 mL of propidium iodide (PI), and incubated at room temperature
for 15 min in dark. The cover slips were inverted on glass slides,
fixed in 2% formaldehyde, and visualized under confocal
microscope.
Western blot analysis of granulosa cell p53. The cultured
granulosa cells were lysed in buffer (150 mM NaCl, 500 mM Tris,
10 mM EDTA) supplemented with protease inhibitors (1 mg/ml
aprotinin, 1 mg/ml pepstatin, 1 mg/ml leupeptin, 1 mM PMSF,
1 mg/ml trypsin inhibitor) and 1% Triton X-100, and centrifuged
at 5,000 rpm for 10 min at 4uC. The supernatant was collected
and estimated for protein concentration. Fifty microgram of total
protein from each sample was resolved on a 10% sodium dodecyl
sulfate polyacrylamide gel and transferred onto immobilon-P
membranes. The membrane was incubated with 5% blocking
solution (Tris-buffered saline [TBS] containing 0.1% Tween-20,
5% non-fat dried milk) for 2 h, washed twice with TBS containing
0.1% Tween-20, and incubated for 4 h with rabbit polyclonal
anti-p53 antibody (1:500 dilution) and anti-b-actin antibody
(1:1000). HRP-conjugated secondary mouse anti-rabbit antibody
(1:2000) was added and peroxide activity was visualized by
enhanced chemiluminescence and exposure to X-Ray film.
Densitometric quantification of signals was done by Image-J
software. The data were expressed as p53 to b-actin ratio.
Immunofluorescence detection of granulosa cell p53
expression. Granulosa cells collected from immature control
rat ovaries were grown on four-chambered slides and incubated
for 24 h with 50 nM galactose in the presence or absence of E2
(100 pg/ml and 1 ng/ml) or FSH (25 ng/ml and 100 ng/ml). The
cells were washed with PBS and fixed for 10 min in ice-cold
absolute methanol at 220uC. The slides were dried, rinsed with
PBS, and incubated with 10% normal goat serum in PBS for
30 min to suppress non specific binding. After removing the serum
solution, the slides were incubated overnight at 4uC with mouse
monoclonal p53 antibody (1:200 dilution) in PBS containing 1.5%
normal goat serum. The slides were washed and incubated for 2 h
in dark with Alexa 633 anti-mouse secondary antibody (1:400
dilution) in PBS containing 1.5% normal goat serum. Finally, the
slides were thoroughly washed in PBS, mounted with DAPI-
containing media, and observed under confocal microscope.
Statistical analyses
The data were expressed as mean 6 standard error of the mean
(SEM), where ‘n’ refers to the number of animals or determina-
tions. All treatments of the granulosa as well as theca cells in
culture with either FSH/LH or serum samples were carried out in
triplicate, and each experiment was repeated at least twice. Given
that the numbers of determinations were low, two-tailed Student’s
t-test was used to analyse the significance of differences between
the experimental and control observations. A difference was
considered statistically significant at P,0.05.
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